title: The postpartum cardiovascular risk factor profile of women with isolated hyperglycemia at 1-hour on the oral glucose tolerance test in pregnancy.
abstract: OBJECTIVE
  Women with gestational diabetes mellitus (GDM) have an enhanced cardiovascular risk factor profile at 3-months postpartum and an elevated risk of future cardiovascular disease, as compared to their peers. Recently, it has emerged that even mild dysglycemia on antepartum oral glucose tolerance test (OGTT) predicts an increased risk of future cardiovascular disease, although it is not known whether there exists an identifiable high-risk subgroup within this patient population. Since gestational impaired glucose tolerance (GIGT) due to isolated hyperglycemia at 1-h during the OGTT (1-h GIGT) bears metabolic similarity to GDM, we hypothesized that, like GDM, 1-h GIGT may predict a high-risk postpartum cardiovascular phenotype.
  
  
  RESULTS
  In this prospective cohort study, 485 women underwent antepartum OGTT, followed by cardiovascular risk factor assessment at 3-months postpartum. The antepartum OGTT identified 4 gestational glucose tolerance groups: GDM (n = 137); 1-h GIGT (n = 39); GIGT at 2- or 3-h (2/3-h GIGT)(n = 50); and normal glucose tolerance (NGT)(n = 259). After adjustment for age, ethnicity, breastfeeding and waist circumference, mean levels of the following cardiovascular risk factors progressively increased from NGT to 2/3-h GIGT to 1-h GIGT to GDM: LDL cholesterol (p = 0.0026); total cholesterol:HDL (p = 0.0030); apolipoprotein B (p = 0.004); apolipoprotein B:apolipoprotein A1 (p = 0.026); leptin (p = 0.018); and C-reactive protein (p = 0.011).
  
  
  CONCLUSIONS
  Amongst women without GDM, 1-h GIGT predicts an enhanced postpartum cardiovascular risk factor profile. It thus emerges, that amongst young women with mild dysglycemia in pregnancy, those with 1-h GIGT may comprise an unrecognized patient population at risk for future cardiovascular disease.
authors.affiliation: Leadership Sinai Centre for Diabetes, 60 Murray Street, Toronto, Ontario, Canada. rretnakaran@mtsinai.on.ca
authors.forename: R
authors.initials: R
authors.lastname: Retnakaran
authors.forename: Y
authors.initials: Y
authors.lastname: Qi
authors.forename: M
authors.initials: M
authors.lastname: Sermer
authors.forename: P W
authors.initials: PW
authors.lastname: Connelly
authors.forename: A J
authors.initials: AJ
authors.lastname: Hanley
authors.forename: B
authors.initials: B
authors.lastname: Zinman
mesh_terms: D000328:Adult; D001055:Apolipoproteins B / Q000097:blood; D002097:C-Reactive Protein / Q000032:analysis; D002318:Cardiovascular Diseases / Q000097:blood* / Q000209:etiology / Q000503:physiopathology; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D016640:Diabetes, Gestational / Q000097:blood / Q000503:physiopathology; D005260:Female; D018149:Glucose Intolerance / Q000097:blood / Q000150:complications / Q000503:physiopathology; D005951:Glucose Tolerance Test; D006801:Humans; D006943:Hyperglycemia / Q000097:blood* / Q000150:complications / Q000503:physiopathology; D020738:Leptin / Q000097:blood; D049590:Postpartum Period / Q000378:metabolism*; D011247:Pregnancy / Q000097:blood*; D011446:Prospective Studies; D012307:Risk Factors
chemical_list: D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D020738:Leptin; D002097:C-Reactive Protein